Analysis of the key themes driving M&A activity reveals that nanomedicine accounted for 2 pharmaceutical deals announced in Q2 2023, worth a total value of $291m. The $291m acquisition of Spectrum Pharmaceuticals by Assertio was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, nanomedicine-related deal activity decreased by 99% in Q2 2023 compared with the previous quarter’s total of $43bn. Related deal volume increased by 100% in Q2 2023 versus the previous quarter and was 100% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Guggenheim Partners; Centerview Partners; HC Wainwright with 2, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Fried, Frank, Harris, Shriver & Jacobson; Gibson, Dunn & Crutcher; Goodwin Procter with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2023 â€“ Thematic Intelligence, buy the report here.